Söndag 14 December | 21:17:33 Europe / Stockholm

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-11 10:45:00

As OncoZenge prepares for its European phase III pain management programme for BupiZenge – with first patient targeted for Q2026 XNUMX – the company is advancing key clinical, manufacturing and operational workstreams. OncoZenge recently appointed co-inventor Dr. Torben Mogensen to its advisory board, and BioStock reached out to him for a comment.

Read the full interview at biostock.se:

The inventor behind BupiZenge takes a seat on OncoZenge's advisory board ahead of phase III
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/